Heterotopic Ossification | CHOP Research Institute
 

Heterotopic Ossification

Published on
Jan 31, 2022
Identified by CHOP researchers, palovarotene is the first drug approved (in Canada) for fibrodysplasia ossificans progressiva, a severe bone disease.

Biomedical research in the Pacifici Laboratory spans three decades and has explored mechanisms of skeletal development and growth in fetal and postnatal life.

Dr. Pacifici's biomedical research spans three decades and has explored mechanisms of skeletal development and growth in fetal and postnatal life. Specifically, his focus has been on identifying the cellular and molecular mechanisms that regulate the differentiation of progenitor cells and permit assembly of distinct skeletal structures, and on aberrations of these mechanisms in pediatric skeletal disorders.

E-mail:
pacificim [at] chop.edu